Navigation Links
Study suggests caution and further studies on drugs used to treat macular degeneration
Date:10/25/2012

LA JOLLA, CA October 24, 2012 Millions of people with "wet" macular degeneration are prescribed a class of medication known as anti-VEGF drugs. But now scientists at The Scripps Research Institute (TSRI) have found that a drastic reduction of VEGF activity may do more harm than good.

In the new study, the researchers deleted the gene for the blood-vessel growth factor VEGF, which has been implicated in stimulating abnormal blood vessel growth in a range of cancers and eye diseases, from cells in the retinas of adult mice. The results showed that without VEGF a large subset of light-sensing cells lost their main blood supply and shut down, causing severe vision loss.

"It's becoming clear that VEGF has a critical function in maintaining the health of the retina, and we need to preserve that critical function when we treat VEGF-related conditions," said TSRI Professor Martin Friedlander, MD, PhD, senior author of the new study, which appears in the November 2012 issue of the Journal of Clinical Investigation.

Major Target for Drug Developers

VEGF (vascular endothelial growth factor) has long been a major target for drug developers. Tumors often overproduce VEGF to stimulate local blood vessel growth and thus keep their fast-dividing cells well supplied with oxygen and nutrients. Low-oxygen conditions in the eyes of elderly or diabetic individuals also can trigger the overproduction of VEGF, resulting in a vision-destroying bloom of abnormal, leaky retinal blood vessels.

Several anti-VEGF drugs (such as Lucentis (ranibizumab), Macugen (pegaptanib), Eylea (aflibercept) and Avastin (bevacizumab)) are already in use, and dozens more are in clinical trials against cancers and common eye disorders such as wet macular degeneration.

However, to date there have not been extensive studies on the effects of such drugs on the normal role of VEGF, in part because it is hard to generate adult animals that l
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Fossil study helps pinpoint extinction risks for ocean animals
2. Forest killer plant study explores rapid environmental change factors
3. Pitt biologist receives $2 million to study genetic diversity of plants worldwide
4. Study: DNA barcoding can ID natural health products
5. Joint UT study: Reading food labels helps shoppers stay thinner
6. Sandia shows monitoring brain activity during study can help predict test performance
7. New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause
8. The George Washington University Researcher received $1.7 million to study solar cement
9. Risk of developing diabetes higher in neighborhoods that arent walk-friendly: Study
10. Rice to take part in $10.8 million study of hemoglobin toxicity
11. Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study suggests caution and further studies on drugs used to treat macular degeneration
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... being tested at the National Institute of Standards ... a recent paper,* NIST scientists used surface-enhanced Raman ... optical qualities that make them superior for chemical ... nanoparticles may one day be used in a ...
... the internal head skeleton of Tiktaalik roseae ... step in the evolutionary transition from fish to animals that ... this week,s issue of the journal Nature , show ... changes not only to appendages (fins to limbs) but also ...
... While an international seed bank in a Norwegian island has ... U.S. scientists has just published an article outlining a different ... wild species at intervals in the future effectively ... Bioscience , Steven J. Franks of Fordham University, Susan ...
Cached Biology News:Gold nanostars outshine the competition 2Details of evolutionary transition from fish to land animals revealed 2Scientists propose the creation of a new type of seed bank 2Scientists propose the creation of a new type of seed bank 3
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... Mass., Jan. 4, 2011 Interleukin Genetics, Inc. (OTC ... will present at the Biotech Showcase 2011, taking place ... 2011.  The corporate presentation will include a company overview ... January 10 at 3:45 p.m. in the Mission II ...
... 4, 2011 Reportlinker.com announces that a new ... Emerging Opportunities in Biosimilar and ... Executive SummaryThe biosimilar and ... in a grand manner following a series of ...
... Reportlinker.com announces that a new market research ... Financial Health of Biotechnology and Drugs Industry ... http://www.reportlinker.com/p0357094/Financial-Health-of-Biotechnology-and-Drugs-Industry-in-India-and-China.html The research services examines ... companies across 2 broad parameters- Excellence in financial ...
Cached Biology Technology:Interleukin Genetics, Inc. to Present at Biotech Showcase 2011 2Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets 2Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China 2
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
... Nucleon HT, 1 kit. Facilitates the simple, ... sections and hard tissue requiring proteinase K ... quality DNA from 50 preparations of up ... DNA/RNA Synthesis & Purification, Purification and Amplification ...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: